Kentucky Statutes 217.5401 – Definitions for KRS 217.5401 to 217.5408
Current as of: 2024 | Check for updates
|
Other versions
As used in KRS § 217.5401 to KRS § 217.5408:
(1) “Biological product” means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, protein other than a chemically synthesized polypeptide, allergenic product or analogous product, or arsphenamine or derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings;
(2) “Device” has the same meaning as in KRS § 217.015; (3) “Drug” has the same meaning as in KRS § 217.015;
(4) “Eligible patient” means an individual who meets the requirements of KRS
217.5403;
(5) “Health care provider” means a licensed physician, a licensed advanced practice registered nurse, or a licensed physician assistant;
(6) “Health facility” has the same meaning as in KRS § 216B.015;
(7) “Investigational drug, biological product, or device” means a drug, biological product, or device that:
(a) Has successfully completed Phase I of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration; and
(b) Remains under investigation in a United States Food and Drug
Administration-approved clinical trial;
(8) “Terminal illness” means a progressive disease or a medical or surgical condition that:
(a) Entails significant functional impairment;
(b) Is not considered by a treating health care provider to be reversible even with administration of a treatment currently approved by the United States Food and Drug Administration; and
(c) Without life-sustaining procedures, will result in death; and
(9) “Written informed consent” means a written document that meets the requirements of KRS § 217.5404.
Effective: June 29, 2017
History: Created 2017 Ky. Acts ch. 65, sec. 1, effective June 29, 2017.
(1) “Biological product” means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, protein other than a chemically synthesized polypeptide, allergenic product or analogous product, or arsphenamine or derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings;
Terms Used In Kentucky Statutes 217.5401
- Device: means any instrument or contrivance other than a firearm which is intended for trapping, destroying, repelling, or mitigating any pest or any other form of plant or animal life other than man and other bacteria, virus, or other microorganisms on or in living man or other living animals. See Kentucky Statutes 217.544
- Treatment: when used in a criminal justice context, means targeted interventions
that focus on criminal risk factors in order to reduce the likelihood of criminal behavior. See Kentucky Statutes 446.010 - Trial: A hearing that takes place when the defendant pleads "not guilty" and witnesses are required to come to court to give evidence.
(2) “Device” has the same meaning as in KRS § 217.015; (3) “Drug” has the same meaning as in KRS § 217.015;
(4) “Eligible patient” means an individual who meets the requirements of KRS
217.5403;
(5) “Health care provider” means a licensed physician, a licensed advanced practice registered nurse, or a licensed physician assistant;
(6) “Health facility” has the same meaning as in KRS § 216B.015;
(7) “Investigational drug, biological product, or device” means a drug, biological product, or device that:
(a) Has successfully completed Phase I of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration; and
(b) Remains under investigation in a United States Food and Drug
Administration-approved clinical trial;
(8) “Terminal illness” means a progressive disease or a medical or surgical condition that:
(a) Entails significant functional impairment;
(b) Is not considered by a treating health care provider to be reversible even with administration of a treatment currently approved by the United States Food and Drug Administration; and
(c) Without life-sustaining procedures, will result in death; and
(9) “Written informed consent” means a written document that meets the requirements of KRS § 217.5404.
Effective: June 29, 2017
History: Created 2017 Ky. Acts ch. 65, sec. 1, effective June 29, 2017.